对用于管理阿尔茨海默氏症疾病的基于兰胺的混合物进行全面分析
Yash Pal Singh1,2, Sonima Prasad3, Harish Kumar2,4
1Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, Virginia, USA.
Chemical biology & drug design
|November 4, 2024
概括
本综述探讨了加兰他胺及其混合类型作为阿尔茨海默病 (AD) 的多目标疗法. 这些新型化合物旨在解决复杂的AD病原体,而不仅仅是单一目标的方法.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特征是认知能力下降.
- 关键的病理特征包括粉样β (Aβ) 斑块,神经纤维状结 (NFT) 和神经递质失衡,特别是乙胆 (ACh).
- 当前的治疗策略往往集中在单一的目标上,这些目标对于像AD这样的复杂疾病来说是不够的.
研究的目的:
- 为阿尔茨海默病治疗提供胺及其混合类型的全面概述.
- 突出这些多标治疗剂的设计和合成的最新进展.
- 审查基于胺的化合物的结构活性关系 (SAR) 分析.
主要方法:
- 在阿尔茨海默病的研究中对胺和其混合类型的文献综述.
- 对加兰胺支架应用的杂交技术的分析.
- 检查设计,合成和SAR研究的胺衍生物.
主要成果:
- 作为一种乙胆酶 (AChE) 抑制剂的加兰胺,是开发多位药物的核心支架.
- 加兰大胺的混合类型在解决多个AD病理因素方面表现有前途.
- 最近的研究重点是创新的设计和合成途径,以提高效率.
结论:
- 多重向疗法,特别是胺混合物,为阿尔茨海默病的管理提供了一个有希望的途径.
- 对设计,合成和SAR的持续研究对于优化这些治疗剂至关重要.
- 混合化策略代表了对抗AD复杂性质的重大进展.
相关概念视频
01:22Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
01:26Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
01:24Parkinson's Disease: Treatment
224
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
224
01:23Antidepressant Drugs: MAOIs and Other Agents
196
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
196
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
98
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
98